Medical Marijuana Stocks

[hotlinktuna]

See this pr on NDEV .325 and see why it may be one of the best MJ plays available:
Novus Initiates Medical Cannabis Worker's Comp Package

Accesswire AccesswireNovember 2, 2016
Recreational Users Will Become Medical Users

MIAMI, FL / ACCESSWIRE / November 2, 2016 / Novus Acquisition and Development, Corp. (OTC Markets: NDEV), the nation's first healthcare insurance carrier/aggregator in the medical cannabis sector demonstrates how their MedPlan will capture market share of recreational users and convert them to medical users in California.

With the impending approval of Proposition 64 in California, Novus has put into operation, through their insurance subsidiary WCIG Insurance Services, Inc., a supplemental Workers Compensation Program that will include medical marijuana for patients in the State of California.

How the MedPlan was derived was based on the Workers' Compensation Insurance Rating Bureau's Actuarial assessment, that workers' compensation premiums in California continue to grow at double-digit rates. The state's workers' comp written premium accounts for more than a quarter of the U.S. total, but only 12 percent of America's workforce, according to the report. Additionally, to make matters worse, the California coverage compares poorly with the rest of the nation

How does California's workers' comp and Novus' supplemental medical marijuana insurance coverage benefit patient and employers interests? Four principal factors: a) California has the highest permanent disability claims in the nation with an inherent on going pain management crisis, b) the state has among the highest claims in terms of medical costs, c) it has a high cost of delivering insurance benefits and; d) another driver of California's higher premiums is the state's medical treatment costs.

How we approached solving the problem is by implementing a supplemental workers compensation program with Novus' infrastructure with California marijuana dispensaries. Then instrumentally delivering a supplemental worker's compensation plan will ease insurers and employers burdens by allowing Novus to procure, in network, a consortia of physicians that will take in patients, generate more medical marijuana recommendations for the protocol for pain management and other aliments to ease suffering. What makes this of value for insurers and employers is that California worker's compensation premiums will decrease losses because medical marijuana and Novus premiums are affordable.

Once the ballot initiatives in California is approved under Proposition 64 Novus will take advantage of three areas a) the abatement of taxation for medical marijuana cardholders b) many doctors are approving medical cannabis and writing recommendation forms for patients because of, c) the opioids crisis, many California doctors are writing less prescriptions for opioids and combining it with medical cannabis for pain management. The end result will be that Novus will get an increase in patient/member signups from the overlapping of recreational users that become medical users under this program.

The graphic below shows the percentile range and the overlying of cannabis users in medical (33%) versus recreation (55%) users, coinciding with worker's comp claims, which is estimated at 12%.


NDEV 2nd Quarter Financial Filing: http://bit.ly/2cJ3Efj

About Novus

Novus Acquisition & Development Corp. (NDEV), through its subsidiary WCIG Insurance, provides health insurance and related insurance solutions within the wellness and medical marijuana industries in states where legal programs exist. Novus has positioned itself to gain market share within many lines of insurance business within and outside of the MMJ sector.

Novus will work as outside developers and will not cultivate, handle, transport grow, extract, dispense, put up for sale, put on the market, vend, deliver, supply, circulate, or trade cannabis or any substances that violate the United States law or the Controlled Substances Act, nor does it intend to do so in the future and will continue to follow state and federal laws. The statements made about specific products have not been evaluated by the United States Food and Drug Administration (FDA) and are not intended to diagnose, treat, cure or prevent disease. All information provided on these press releases or any information contained on or in any product label or packaging is for informational purposes only and is not intended as a substitute for advice from your physician or other health care professional. Once a push notification is competed the transaction is solely between the state-licensed dispensary and the registered patient.

The state laws are in conflict with the federal Controlled Substances Act. The current administration has effectively stated that it is not an efficient use of resources to direct federal law enforcement agencies to prosecute those lawfully abiding by state designated laws, allowing the use and distribution of medical marijuana. However, there is no guarantee that the current administration, nor any future administration, will not change this policy and decide to enforce the federal laws strongly. Any such change in the federal government's enforcement of current federal laws could cause significant financial changes to Novus Medical Group. While we do not intend to harvest, distribute or sell cannabis or cannabis related products, we may be harmed by a change in enforcement by federal or state governments.

For more information, check out: http://www.getnovusnow.com
For NDEV 2nd Quarter Financial Filing: http://bit.ly/2cJ3Efj
Learn How Insurance Companies Are Evaluated: http://bit.ly/2ddIYva
Forward-Looking Statements

This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, includes codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. Novus Medical Group disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information

Corporate:
Chairman and CEO
Frank Labrozzi
[e-mail]
855-228-7355

Investors:
Hayden IR
[e-mail]
917-658-7878

SOURCE: Novus Acquisition and Development, Corp.

Though still relatively unknown in the MJ sector, it is definitely gaining attention deservedly so all imho...tuna